Evaluation of rapid diagnostic tests and conventional enzyme-linked immunosorbent assays to determine prior dengue infection.
In September 2018, the World Health Organization recommended that pre-vaccination screening be used with the tetravalent dengue vaccine (CYD-TDV), to ensure that only individuals with evidence of prior dengue infection (PDI) are vaccinated. Dengue rapid diagnostic tests (RDTs) would offer a potential solution for pre-vaccination screening at the point-of-care, but data on performance of available RDTs for identifying PDI are limited. We determined the suitability of four dengue RDTs and two conventional enzyme-linked immunosorbent assays (ELISAs) to identify PDI and evaluated cross-reactivity with co-circulating flaviviruses. Specificity was assessed using 534 dengue negative (determined by 50% plaque reduction neutralization test [PRNT50]) serum samples from USA (n = 229) and dengue-endemic regions (n = 305). Sensitivity was assessed using 270 samples from recent (n = 90) or remote (n = 90) virologically-confirmed prior dengue cases, and dengue PRNT50 positive samples (n = 90). Cross-reactivity was assessed in dengue seronegative samples that were seropositive for yellow fever (n = 57), Japanese encephalitis (n = 37), West Nile (n = 59) or Zika (n = 41). Dengue IgG RDTs and the Panbio ELISA exhibited favourable specificities (99-100%), higher than the Focus ELISA (95%). The RDTs had variable sensitivities (40-70%) that were lower than those of the ELISAs (≥90%). Cross-reactivity to other flaviviruses was low with RDTs (≤7%), but more significant with ELISAs (up to 51% for West-Nile and 34% for Zika). No cross-reactivity to any of the four closely-related flaviviruses was observed with the CTK Biotech RDT. For each serotest, sensitivity appeared similar in samples from individuals with recent (<13 months) versus remote (3-4 years) virologically-confirmed PDI. In general, dengue IgG RDTs were found to be more specific and less cross-reactive than the ELISAs, but the latter were more sensitive for identifying PDI cases. Currently available RDTs could be temporizing tools for rapid and safe pre-vaccination screening until improved RDTs with increased sensitivity become available.